ArticleBMC infectious diseases2025
Interaction between HBsAg response and the prognosis of patients with HBV-associated HCC receiving anti-PD-1/PD-L1.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProgrammed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) inhibitors are widely used in advanced hepatocellular carcinoma (HCC). Hepatitis B virus (HBV) is a major etiology of HCC, yet predictive biomarkers for anti-PD-1/PD-L1 efficacy in HBV-related HCC (HBV-HCC) remain scarce.
methodsThis retrospective study analyzed 76 patients with HBV-HCC treated at Nanjing Medical University Affiliated Taizhou People’s Hospital (2019–2023). Demographic, biochemical, and serial Hepatitis B surface antigen (HBsAg) data were collected. Primary endpoints were progression-free survival (PFS) and overall survival (OS); secondary endpoints included HBV reactivation and hepatitis. Statistical analyses involved t-tests, chi-square tests, and Kaplan–Meier with log-rank tests. All patients were HBsAg-positive and received antiviral therapy. Groups were divided based on anti-PD-1/PD-L1 treatment, with the treatment group further subclassified by increasing or decreasing HBsAg trends.
resultsBaseline characteristics showed no significant differences. The anti-PD-1/PD-L1 group exhibited significantly longer PFS (P < 0.001) and OS (P = 0.039). Within the treatment group, decreasing HBsAg was associated with improved OS (P = 0.027). HBV reactivation rates showed no significant difference, nor did HBV-associated hepatitis (4.7% vs. 9.1%; 4.65% vs. 3.03%).
conclusionA decline in HBsAg may indicate better treatment response and survival in HBV-HCC patients receiving PD-1/PD-L1 inhibitors, without increasing HBV reactivation or hepatitis risk, supporting its safety. PD-1/PD-L1 inhibitors may promote HBsAg reduction, though further studies are needed to clarify the mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.